RECRUITING

Therapeutic Omegas for Triglyceride Suppression

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study plans to learn more about how an omega-3 fatty acid supplement effects triglyceride levels in pregnancy. Triglycerides are a type of fat found in your blood. Your body converts extra calories into triglycerides to be stored and used later for energy. It is normal for triglyceride levels to go up during pregnancy however some women have levels that are \~30-40% higher than normal when they reach their third trimester of pregnancy. Having high triglycerides in pregnancy may be related to an increased chance of having a baby that is large for their age. The goal of this study is to determine if taking an omega-3 fatty acid supplement can slow the rise in triglyceride levels later in pregnancy.

Official Title

Pilot RCT Intervention Targeting Elevated Triglycerides With a Point-of-Care Meter and Omega-3 Fatty Acids to Normalize Triglycerides and Fetal Growth

Quick Facts

Study Start:2021-11-29
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04349475

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:0 Years to 39 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Pregnant women between the ages of 21-39 yrs
  2. * Pre-pregnancy BMI 28-39
  3. * Fasting Triglyceride ≥120 mg/dL measured by 15 wks
  1. * Pre-gestational diabetes or prediabetes
  2. * History of gestational diabetes,
  3. * History of pre-eclampsia, spontaneous pre-term delivery, or gestational hypertension \<34wks
  4. * Tobacco or illicit substance use
  5. * Chronic steroid use

Contacts and Locations

Study Contact

Teri L Hernandez, PhD
CONTACT
303-724-8538
Teri.Hernandez@cuanschutz.edu
Linda A Barbour, MD
CONTACT
303-724-3954

Principal Investigator

Teri L Hernandez, PhD
PRINCIPAL_INVESTIGATOR
University of Colorado - Anschutz Medical Campus

Study Locations (Sites)

University of Colorado/Anschutz Medical Campus
Aurora, Colorado, 80045
United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

  • Teri L Hernandez, PhD, PRINCIPAL_INVESTIGATOR, University of Colorado - Anschutz Medical Campus

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-11-29
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2021-11-29
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • triglycerides
  • glucose
  • adiposity
  • Air displacement plethysmography
  • Continuous glucose monitoring

Additional Relevant MeSH Terms

  • Pregnancy